Lincoln Pharmaceuticals

574.10
+14.80
(2.65%)
Market Cap
1,149.91 Cr
EPS
46.58
PE Ratio
12.54
Dividend Yield
0.32 %
Industry
Healthcare
52 Week High
979.50
52 Week Low
499.00
PB Ratio
1.75
Debt to Equity
0.00
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from1 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+100.00 %
+100.00 %
Hold
Hold0.0 %
0.0 %
Sell
Sell0.0 %
0.0 %
Competitors LTP Market Cap (₹ Cr.) P/E Ratio Revenue (₹ Cr.) YoY Revenue Growth % Net Profit (₹ Cr.) YoY Profit Growth % RSI
1,770.00
#1 4,24,682.29
34.87
#1 49,887.20
12.06
#1 9,648
13.77
59.55
5,763.00
1,52,989.54
72.74
8,184.00
0.89
1,600
#1 64.53
50.90
1,495.70
1,20,794.97
23.51
26,520.70
14.17
4,155
47.38
55.43
3,247.70
1,09,916.93
58.33
10,785.70
11.59
1,656
13.54
59.71
2,427.70
1,00,161.69
48.93
10,615.60
19.57
1,942
-16.38
56.35
1,151.45
96,083.36
#1 17.86
28,905.40
12.36
5,578
1.69
45.59
2,095.70
95,677.29
31.98
20,141.50
#1 19.94
1,936
38.82
56.82
901.90
90,752.24
19.78
19,831.50
13.82
3,831
29.92
49.00
1,176.35
68,322.60
19.09
29,559.20
17.55
3,169
-10.04
55.70
29,909.30
63,555.17
47.09
6,097.20
10.80
1,201
16.01
48.49
Growth Rate
Revenue Growth
15.43 %
Net Income Growth
27.98 %
Cash Flow Change
61.03 %
ROE
8.48 %
ROCE
2.31 %
EBITDA Margin (Avg.)
4.20 %

Quarterly Financial Results

Quarterly Financials
Mar 2015
Jun 2015
Sept 2015
Dec 2015
Mar 2016
Jun 2016
Sept 2016
Dec 2016
Mar 2017
Jun 2017
Sept 2017
Dec 2017
Mar 2018
Jun 2018
Sept 2018
Dec 2018
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Revenue
79
73
91
105
129
93
78
74
119
152
93
83
68
102
107
85
78
98
115
102
83
106
127
116
82
124
131
123
105
130
146
140
116
143
165
158
150
158
171
156
Expenses
71
64
84
95
117
74
63
62
115
143
74
64
58
77
84
71
68
78
88
85
70
82
96
95
64
97
98
96
85
107
112
107
96
115
125
117
124
125
133
123
EBITDA
7
9
8
10
12
19
15
12
4
10
18
19
11
26
24
14
10
20
27
16
13
24
30
21
18
27
33
26
19
23
35
33
21
28
40
41
25
33
38
33
Operating Profit %
9 %
12 %
8 %
9 %
3 %
17 %
16 %
12 %
3 %
5 %
17 %
20 %
14 %
23 %
19 %
16 %
14 %
20 %
22 %
13 %
11 %
21 %
24 %
17 %
19 %
21 %
23 %
20 %
17 %
14 %
21 %
20 %
15 %
15 %
20 %
20 %
13 %
15 %
18 %
16 %
Depreciation
1
1
1
1
1
1
1
2
1
1
2
1
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
3
3
3
3
3
3
3
Interest
3
2
2
2
4
2
2
1
1
2
2
1
1
1
2
1
1
1
1
1
-1
1
-0
0
1
0
0
0
1
0
0
0
1
0
0
0
1
0
0
1
Profit Before Tax
3
8
9
10
6
15
12
9
1
7
15
16
8
23
20
11
8
18
25
13
12
21
29
18
15
25
31
24
17
21
32
31
17
26
37
38
22
30
35
29
Tax
1
2
2
3
2
4
3
3
-0
2
4
5
1
7
5
2
-1
5
6
2
3
6
8
5
3
7
8
6
6
6
8
9
4
6
9
10
4
6
8
8
Net Profit
2
7
7
7
4
11
9
7
1
5
11
12
7
16
15
9
9
13
19
11
9
15
21
14
13
18
23
18
11
15
24
22
13
19
28
28
19
24
26
21
EPS in ₹
1.35
4.01
4.10
3.95
2.46
6.99
5.42
3.27
0.66
2.46
5.65
5.79
3.42
8.03
7.50
4.57
4.25
6.33
9.46
5.46
4.47
7.63
10.46
6.73
6.29
8.85
11.50
8.79
5.50
7.49
11.84
10.79
6.27
9.49
13.81
14.00
9.28
11.82
13.15
10.37

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Total Assets
258
275
305
347
366
389
452
534
587
700
Fixed Assets
66
99
103
117
121
123
111
132
151
179
Current Assets
177
147
181
218
224
248
309
353
367
447
Capital Work in Progress
3
3
7
0
2
0
2
16
7
4
Investments
0
0
10
11
18
34
81
97
91
139
Other Assets
190
174
186
219
225
232
259
290
339
379
Total Liabilities
258
275
305
347
366
389
452
534
587
700
Current Liabilities
111
100
91
105
85
66
76
91
72
92
Non Current Liabilities
33
34
22
18
11
10
10
11
13
15
Total Equity
114
141
193
225
270
314
366
433
503
593
Reserve & Surplus
95
117
172
204
249
293
346
413
482
573
Share Capital
16
16
20
20
20
20
20
20
20
20

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Net Cash Flow
-1
-0
-0
4
-1
7
-1
-5
-2
1
Investing Activities
7
-42
-26
-12
-18
-31
-64
-78
-37
-57
Operating Activities
25
45
25
27
53
75
69
76
39
63
Financing Activities
-32
-3
0
-11
-36
-38
-6
-3
-5
-5

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Promoter
37.26 %
37.78 %
40.28 %
42.08 %
42.05 %
44.08 %
44.08 %
46.34 %
47.00 %
48.67 %
50.53 %
49.80 %
49.53 %
49.78 %
49.78 %
49.78 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
2.59 %
0.00 %
3.93 %
3.95 %
5.19 %
5.16 %
DIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.05 %
0.04 %
0.00 %
0.00 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
42.89 %
40.52 %
40.20 %
38.88 %
38.68 %
39.12 %
39.12 %
36.61 %
37.03 %
37.32 %
37.47 %
37.78 %
37.36 %
37.10 %
36.14 %
36.71 %
Others
19.85 %
21.70 %
19.52 %
19.04 %
19.27 %
16.80 %
16.79 %
17.06 %
15.97 %
14.01 %
9.41 %
12.42 %
9.13 %
9.14 %
8.89 %
8.35 %
No of Share Holders
21,415
26,420
30,274
31,913
32,447
31,902
31,731
29,846
29,088
27,480
28,670
29,316
31,375
29,967
31,330
31,848

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 1.2 1.5 1.5 1.5 1.5 1.5 1.5 1.8 0.00
Dividend Yield (%) 0.00 0.56 0.71 1.16 0.67 0.48 0.44 0.26 0.33 0.00

Corporate Action

Announcements

Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulation 2015.5 days ago
Closure of Trading Window8 days ago
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 14, 2025
Integrated Filing (Financial)Feb 13, 2025
UN AUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED ON 31.12.2024 Feb 13, 2025
Board Meeting Outcome for OUTCOME OF THE BOARD MEETINGFeb 13, 2025
Board Meeting Intimation for Consideration And Approval Of Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Third Quarter And Nine Months Ended 31St December 2024.Feb 05, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 07, 2025
Intimation Of Change Of Name Of Registrar And Share Transfer Agent (RTA) Of The Company Jan 03, 2025
Clarification On Volume/Price Movement Sought By BSE LimitedDec 06, 2024
Clarification sought from Lincoln Pharmaceuticals LtdDec 06, 2024
Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 15, 2024
UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED ON 30.09.2024Nov 14, 2024
Board Meeting Outcome for OUTCOME OF BOARD MEETINGNov 14, 2024
Board Meeting Intimation for Consider And Approve The Un-Audited Financial Results For The Quarter Ended 30.09.2024.Nov 05, 2024
Minutes Of 30Th Annual General Meeting Of The Company.Oct 11, 2024
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Oct 07, 2024
Shareholder Meeting / Postal Ballot-Scrutinizer''s ReportOct 03, 2024
Submission Of Voting Results Of 30Th A.G.M. Along With The Scrutinizer Report As Per Regulation 44 Of SEBI (LODR) Regulation 2015.Oct 03, 2024
Shareholder Meeting / Postal Ballot-Outcome of AGMSep 30, 2024
Closure of Trading WindowSep 23, 2024
Business Responsibility and Sustainability Reporting (BRSR)Sep 09, 2024
Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 07, 2024
Reg. 34 (1) Annual Report.Sep 06, 2024
Notice Of 30Th Annual General Meeting Of The Company.Sep 06, 2024
Corporate Action-Fixes Book Closure For Determining The Dividend, If Approved At The AGMAug 29, 2024
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 28, 2024
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 09, 2024
Un-Audited Financial Results For The Quarter Ended 30-June-2024Aug 08, 2024
Board Meeting Outcome for Outcome Of Un-Audited Financial Results For The Quarter Ended 30-June-2024Aug 08, 2024
Board Meeting Intimation for Board Meeting Intimation To Consider And Approve The Un-Audited Financial Results For The Quarter Ended On June 30, 2024.Jul 30, 2024
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Jul 06, 2024
Closure of Trading WindowJun 26, 2024
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011Jun 11, 2024
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011Jun 03, 2024
Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 24, 2024
Shareholder Meeting / Postal Ballot-Scrutinizers ReportMay 20, 2024
Shareholder Meeting / Postal Ballot-Outcome of Postal_BallotMay 20, 2024
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptMay 18, 2024
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 17, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 16, 2024
FINANCIAL HIGHLIGHTS WITH RESPECT TO AUDITED FINANCIAL RESULTS FOR QUARTER AND YEAR ENDED MARCH 31, 2024May 16, 2024
Corporate Action-Board approves DividendMay 16, 2024
Audited Financial Results For Quarter And Year Ended 31St March, 2024May 16, 2024
Board Meeting Outcome for Outcome Of Audited Financial Results For Quarter And Year Ended On 31St March, 2024May 16, 2024
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 15, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 15, 2024
Corporate Action-Board to consider DividendMay 08, 2024
Board Meeting Intimation for Intimation Of Board Meeting To Consider And Approve Audited (Standalone & Consolidated) Financial Results Of The Company For The Quarter And Year Ended On March 31, 2024.May 08, 2024
Certificate Under Regulation 40 (9) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.Apr 22, 2024

Technical Indicators

RSI(14)
Neutral
45.63
ATR(14)
Less Volatile
23.75
STOCH(9,6)
Neutral
45.86
STOCH RSI(14)
Overbought
94.09
MACD(12,26)
Bullish
7.24
ADX(14)
Weak Trend
22.38
UO(9)
Bearish
30.59
ROC(12)
Uptrend And Accelerating
7.50
WillR(14)
Neutral
-40.42